A Phase 3b/4 Randomized Double Blind Placebo Controlled Study Of Methotrexate (MTX) Withdrawal In Subjects With Rheumatoid Arthritis (RA) Treated With Tofacitinib 11mg Modified Release (MR) Formulation

Trial Profile

A Phase 3b/4 Randomized Double Blind Placebo Controlled Study Of Methotrexate (MTX) Withdrawal In Subjects With Rheumatoid Arthritis (RA) Treated With Tofacitinib 11mg Modified Release (MR) Formulation

Recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Tofacitinib (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 30 Sep 2016 Planned End Date changed from 1 Feb 2019 to 1 Mar 2019.
    • 30 Sep 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top